• The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, according to a new study.
  • An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete...
  • Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and metabolic activity in the brains of living Alzheimer’s patients.
  • An emerging molecular imaging technique may provide a way to break the perpetual cycle of abuse of alcoholism. It could signal patients’ heightened risk and lead to targeted drug treatments that reduce the compulsion to drink, said researchers presenting at the 2016 Annual Meeting of the Society of...
  • June 7, 2016 — Blue Earth Diagnostics Ltd. and Siemens’ PETNET Solutions Inc. announced the commercial availability of Axumin (fluciclovine F-18) injection in the United States.
News | Nuclear Imaging | June 24, 2016
Developers of a new portable molecular imaging system debuted their creation at the 2016 Annual Meeting of the Society...
PET-CT, advanced cancer, lean body mass, LBM, SNMMI 2016 study
News | Oncology Diagnostics | June 23, 2016
Cancer patients often experience significant fluctuations in weight and lean body mass (LBM). Neglecting to account for...
blood test, PRRT, neuroendocrine tumors, NETs, somatostatin receptor imaging, SRI, SNMMI 2016 study

NET circulating transcript and chromogranin A (CgA) levels in responders and non-responders. a) Transcripts were significantly reduced at 6-month follow-up compared to pre-treatment values. Non-responders (NR) exhibited significantly elevated levels at 6 months (FUP_6m). This was also significantly higher than in responders (R). b) A significant alteration was noted only for CgA in non-responders (NR) at 6 months. c) Pre-PRRT: NET transcript scores were elevated in 94 percent and CgA in 57 percent. d) Responders: NET transcripts decreased in 88 percent of responders (no change in 12 percent). CgA was unchanged in 47 percent, decreased in 21 percent and was elevated in 32 percent. e) Non-Responders: NET transcripts increased in 90 percent (no change in 10 percent). CgA was unchanged in 33 percent, decreased in 40 percent and was elevated in 27 percent. For NET transcripts, no falsely decreased or increased values occurred in responders or non-responders, respectively. Credit: LuGenIum Consortium for Independent Research & Wren Laboratories

News | Oncology Diagnostics | June 23, 2016
Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor...
PET, neuroinflammation, multiple sclerosis, MS, Adam Rosenberg, SNMMI 2016

A. Increased F-18 TZ3504 uptake was observed in the inflamed lumbar spinal cord of EAE-treated animals in the rat model of MS compared to sham control rats. Representative sagittal, coronal and transverse views of the thoracic and lumbar spine are shown. B. The time activity curve of F-18 TZ3504 uptake in the lumbar spinal cord was significantly higher for the first 30 minutes in EAE-treated rats. C. F-18 TZ3504 was able to cross the blood brain barrier and showed homogeneous distribution in the brain of a healthy nonhuman primate. Image Credit:  Mallinckrodt Institute of Radiology at the Washington University School of Medicine, St. Louis, Mo.

News | PET Imaging | June 23, 2016
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular...
neuroendocrine tumors, NET, radiotherapy dose, PET, SPECT, SNMMI 2016

Comparison of Ga-68-DOTATOC PET/CT with Y-90 DOTATOC PET/CT. Although the positron associated with Y-90 is rarely emitted, there is still sufficient signal to acquire a quantitative PET/CT image of Y-90 DOTATOC after a therapeutic administration. The white arrows indicate kidneys and the yellow arrows tumor. Credit: University of Iowa

News | Nuclear Imaging | June 23, 2016
Aggressive neuroendocrine cancer is something of a dark horse — a rare, elusive and persevering force linked to...
NSCLC, lung cancer, chemotherapy, FDG PET, SNMMI 2016
News | PET Imaging | June 22, 2016
Non-small cell lung cancers (NSCLC) have a collective reputation for not responding very well to chemotherapy....
VASH collimator, DOE, molecular breast imaging, SNMMI 2016

Adding this variable angle slant hole collimator to an existing breast molecular imaging system allows the system to get six times better contrast of cancer lesions in the breast, providing the same or better image quality while also potentially reducing the radiation dose to the patient by half. Technologies developed at DOE’s Jefferson Lab for the variable angle slant hole collimator are included in two filings to the U.S. Patent and Trademark Office. Image courtesy of DOE’s Jefferson Lab.

News | Breast Imaging | June 21, 2016
Preliminary tests have demonstrated that a new device may enable up to six times better contrast of tumors in the...
prostate cancer, biopsy, PET-CT, Ga-68 PSMA, SNMMI 2016 study, Wolfgang Fendler
News | PET-CT | June 20, 2016
Prostate cancer is the leading cancer among men, second only to skin cancer. With surgical removal at the frontline of...
pretargeted radioimmunotherapy, PIRT, colorectal cancer, radionuclide agents, SNMMI 2016, Sarah Cheal

Illustration of three-step DOTA-PRIT based on targeting with an IgG-scFv bispecific antibody (e.g., huA33-C825 for detection and treatment of colorectal cancer) with dual specificity for a tumor-associated antigen (e.g., GPA33) and M-DOTA haptens (e.g., Lu-177 DOTA). Image courtesy of Memorial Sloan Kettering Cancer Center.

News | Radiopharmaceuticals and Tracers | June 20, 2016
An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of...
SNMMI, Image of the Year 2016, PET, Alzheimer's disease, amyloid plaques

Topographical correspondence of tau- but not amyloid-pathology with neuronal dysfunction in Alzheimer’s disease

Right lateral surface of projected z-score images, reflecting deviation from healthy controls

Yellow/red: higher uptake, blue: lower uptake as compared to controls

Image courtesy of G. Bischof, J. Hammes, T. van Eimeren, A. Drzezga, Multimodal Neuroimaging Group, Dept. of Nuclear Medicine, University of Cologne; B. Neumaier, Institute of Radiochemistry and Experimental Molecular Imaging University of Cologne; J. Dronse, O. Onur, J. Kukolja, G. Fink, F. Jessen, Center for Memory Disorders, Depts. of Neurology & Psychiatry, University of Cologne; and K. Fliessbach, Dept. of Neurology, University of Bonn.

Feature | PET Imaging | June 20, 2016
Positron emission tomography (PET) with three different radiotracers can now measure amyloid plaques, tau tangles and...
News | Prostate Cancer | June 17, 2016
Decatur Memorial Hospital, Decatur, Ill., is now offering C-11 choline positron emission tomography (PET)/computed...
Trump, PSA, prostate cancer

Image courtesy of Pixabay.

Blog | Imaging | June 15, 2016
Personalized medical care conjures an image of exactness. Precision. Its realization was once believed attainable...
Michael J. Fox Foundation, MJFF, Parkinson's, PET tracer, competition, SNMMI 2016
News | PET Imaging | June 14, 2016
The Michael J. Fox Foundation (MJFF) announced a $2 million prize for development of a ...
Philips, SNMMI 2016, Vereos digital PET/CT, time-of-flight, IntelliSpace 8.0, nuclear imaging
News | Nuclear Imaging | June 14, 2016
Philips announced it would be showcasing a variety of nuclear imaging solutions at the Society of Nuclear Medicine and...
PET-CT study, alcoholic brain, SNMMI 2016, mGluR5 receptor

Decreased mGluR5 availability in the brain of alcohol dependent individuals compared to healthy subjects. Image courtesy of Department of Nuclear Medicine and Molecular Imagine UZ Leuven, Leuven, Belgium

News | PET-CT | June 13, 2016
An emerging molecular imaging technique may provide a way to break the perpetual cycle of abuse of alcoholism. It could...
Loma Linda University, Siemens PETNET Solutions, PET facility, production and research
News | Nuclear Imaging | June 09, 2016
Loma Linda University and Siemens’ PETNET Solutions Inc. have completed and brought operational a state-of-the-art...
Siemens Healthineers, SNMMI '16, molecular imaging, syngo.via, Biograph Horizon PET/CT, mobile configuration
News | Nuclear Imaging | June 09, 2016
At the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Siemens Healthineers will...
MR

MR prostate image courtesy of Siemens Healthineers

Blog | Imaging | June 08, 2016
Effective screening may be the key to America’s future. Only by catching disease early, before disease can injure the...
nuclear medicine, global market, radiopharmaceuticals, MEDraysintell, SNMMI 2016
News | Nuclear Imaging | June 08, 2016
MEDraysintell estimates that the global market for nuclear medicine (radiopharmaceuticals) reached $4.3 billion in 2015...
NaF-PET/CT, sodium fluoride, advanced prostate cancer, metastases, pilot study
News | PET-CT | June 07, 2016
A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18...
Overlay Init